We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Vitamin D and Calcium Supplementation on Inflammatory Biomarkers and Adypocytokines in Diabetic Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01662193
Recruitment Status : Unknown
Verified August 2012 by Marjan Tabesh, Isfahan University of Medical Sciences.
Recruitment status was:  Recruiting
First Posted : August 10, 2012
Last Update Posted : August 13, 2012
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:

The epidemic of type 2 diabetes is an enormous public health problem in all parts of the world, with 366 million cases by 2030. Chronic inflammation has been postulated to play a role in the pathogenesis of type 2 diabetes. High levels of adiponectin and inflammatory biomarkers are known as a new risk factor for diabetes. There is accumulating evidence suggesting that altered vitamin D and calcium homeostasis affect the development of type 2 diabetes, but it is still unclear whether that effects are through reducing the level of adipocytokines and inflammatory biomarkers or not. This study has been designed to evaluate the effects of vitamin D and calcium supplementations alone and in combination on inflammatory biomarkers and adypocytokines in type 2 diabetic patients.

This study is a single masked, controlled randomized trial with period of 8 weeks. 120 diabetic patients who met the inclusion criteria will enroll in this study. Subjects will randomly assign in to four groups. Randomization will be achieved by permuted blocks with stratification by age, sex, BMI, type of diabetes and dose of medication. Group1 will receive 50000 IU of vitamin D3 per week plus calcium placebo, group2 will received 1000 mg of calcium carbonate per day plus vitamin D placebo, group 3 will receive 50000 IU of vitamin D3 plus 100 of mg calcium carbonate per day and group four will receive calcium and vitamin D placebos. Total cholesterol, HDL, LDL, serum triglyceride, serum glucose, serum insulin, HbA1C, leptin, adiponectin and inflammatory biomarkers such as TNF-alpha, IL-6 and high sensitivity C reactive protein (hs-CRP) will be determine by taking blood samples at the baseline and at the end of intervention. Systolic and diastolic blood pressure and anthropometric measurements (height, weight, hip and waist circumferences) will be measured at the baseline and after 8 weeks of intervention. 3 dietary records and 3 physical activity records will be taken at 2,4 and 6 week of intervention to make sure that all subjects maintain their usual diet and physical activity during intervention.


Condition or disease Intervention/treatment
Nutritional and Metabolic Disease Dietary Supplement: vitamin D3 supplement Dietary Supplement: calcium supplement Dietary Supplement: vitamin D3 and calcium supplement Dietary Supplement: placebo

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Effects of Vitamin D and Calcium Supplementation on Inflammatory Biomarkers and Adypocytokines in Diabetic Patients
Study Start Date : February 2012
Estimated Primary Completion Date : February 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: vitamin D3
vitamin D3 supplement 50000 IU vitamin D3 per week
Dietary Supplement: vitamin D3 supplement
Other Name: cholecalciferol
Experimental: calcium supplement
calcium supplement 1000 mg calcium carbonate daily
Dietary Supplement: calcium supplement
Other Name: calcium carbonate
Experimental: vitamin D and calcium supplement
vitamin D3 and calcium supplementation 50000 IU vitamin D3 per week and 1000 mg calcium carbonate daily
Dietary Supplement: vitamin D3 and calcium supplement
Other Name: cholecalciferol and calcium carbonate
Placebo Comparator: placebo
placebo
Dietary Supplement: placebo


Outcome Measures

Primary Outcome Measures :
  1. change in inflammatory biomarkers from baseline at 8 weeks [ Time Frame: 8 weeks ]
    including:IL-6, TNF-alpha, hs-CRP

  2. change in adipocytokines from baseline at 8 weeks [ Time Frame: 8 weeks ]
    including: adiponectin and leptin


Secondary Outcome Measures :
  1. change in weight (Kg) from baseline at 8 weeks [ Time Frame: 8 weeks ]
  2. change in lipid profile from baseline at 8 weeks [ Time Frame: 8 weeks ]
    including: LDL, HDL, total cholesterol, TG

  3. change in serum Glucose from baseline at 8 weeks [ Time Frame: 8 weeks ]
  4. change in height (Cms) from baseline at 8 weeks [ Time Frame: 8 weeks ]
  5. change in hip circumference (Cms) from baseline at 8 weeks [ Time Frame: 8 weeks ]
  6. change in waist circumference (Cms) from baseline at 8 weeks [ Time Frame: 8 weeks ]
  7. change in serum Insulin from baseline at 8 weeks [ Time Frame: 8 weeks ]
  8. change in HbA1C from baseline at 8 weeks [ Time Frame: 8 weeks ]
  9. change in blood pressure from baseline at 8 weeks [ Time Frame: 8 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • more than 30 years old
  • have no history of renal failure, cancer, liver diseases, thyroid diseases or any other inflammatory diseases
  • have no allergy
  • do not use any tobacco products
  • not using corticosteroids
  • not consuming any kinds of vitamin D or calcium supplement
  • have not more than 4 kilograms weight change during last 3 months

Exclusion Criteria:

  • pregnancy
  • insulin dependent diabetes
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01662193


Contacts
Contact: marjan tabesh, MS 00989131664159 tabesh@hlth.mui.ac.ir

Locations
Iran, Islamic Republic of
Medical School of Isfahan Recruiting
Isfahan, Iran, Islamic Republic of
Contact: esmaillzadeh, PhD       esmaillzadeh@hlth.mui.ac.ir   
Principal Investigator: marjan tabesh, MS         
Sponsors and Collaborators
Isfahan University of Medical Sciences
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Marjan Tabesh, Director, Isfahan University of Medical Sciences
ClinicalTrials.gov Identifier: NCT01662193     History of Changes
Other Study ID Numbers: 190136
First Posted: August 10, 2012    Key Record Dates
Last Update Posted: August 13, 2012
Last Verified: August 2012

Keywords provided by Marjan Tabesh, Isfahan University of Medical Sciences:
Cholecalciferol
Calciol
vitamin D3
Diabetes Mellitus
Diabetes Mellitus Type 2
glucose metabolism disorders
ergocalciferol
calcium
adipicytokines
inflammatory biomarkers

Additional relevant MeSH terms:
Calcium, Dietary
Metabolic Diseases
Vitamins
Vitamin D
Ergocalciferols
Cholecalciferol
Calcium Carbonate
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Antacids
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents